because (1) a larger amount of myocardial damage may lead to more severe atrial stretch, inflammation, hemodynamic changes, and neurohumoral activation 1, 8, 11 and (2) a rapid as well as irregular heart rate may precipitate or exacerbate left ventricular (LV) dysfunction and lead to a further reduction of coronary perfusion and consequently a larger infarct size. 1, 10 Indeed, Gal et al 12 showed that high-sensitivity cardiac troponin T levels, an established marker of myocardial necrosis, 13 are associated with AF in the setting of STEMI. However, these results were questioned by other studies.
14 An explanation for these conflicting results is the lack of a precise and comprehensive approach to directly visualize the amount of myocardial injury in previous studies. Cardiovascular magnetic resonance (CMR) is unique in its ability to provide a comprehensive infarct characterization with high accuracy. 15 Moreover, CMR-determined myocardial salvage, infarct size, and microvascular injury are strongly related with poor clinical outcomes in patients with STEMI. 16 In this large, multicenter cohort of contemporary reperfused patients with STEMI, we aimed to describe whether there is a relationship between the presence of AF, infarct characteristics assessed by CMR imaging and adverse cardiovascular events at 12 months after primary percutaneous coronary intervention (PPCI).
Methods

Study Design
This was a post hoc analysis of data from the multicenter CMR substudy of the AIDA STEMI trial (Abciximab Intracoronary versus Intravenous Drug Application in ST-Elevation Myocardial Infarction). AIDA STEMI was a randomized, open-label, multicenter trial, comparing the effects of intracoronary versus standard intravenous bolus application of abciximab in patients with STEMI undergoing PPCI. 17 The design and principal results of AIDA STEMI as well as of the prospective CMR substudy are reported elsewhere. [17] [18] [19] [20] Briefly, consecutive patients with STEMI presenting <12 hours after symptom onset were included. The CMR substudy enrolled 795 patients at 8 sites and found no significant difference in CMR markers of myocardial injury between both groups. 19 The primary clinical end point was the rate of MACE, defined as a composite of all-cause mortality, nonfatal reinfarction, and new congestive heart failure within 1 year after STEMI. Detailed end point definitions have been published previously. 17, 19 According to the predefined study protocol, standard 12-lead ECGs were recorded in each patient before and 90 minutes after PPCI as well as 24 hours after PPCI (voltage, 10 mm/mV; speed, 25 mm/sec or 50 mm/sec). All ECGs were analyzed by 2 cardiologists blinded to other trial data for the presence or absence of AF. A consensus decision was made in case of conflicting results between both readers. Patients were then categorized into 2 groups according to the presence or absence of AF (Figure) . The local ethics committee approved the study and patients were required to provide written informed consent. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
CMR Imaging
Patients underwent CMR on 1.5 T or 3.0 T scanners during hospitalization for STEMI. 21 The sites were selected based on established expertise in acquiring CMRs in patients with myocardial infarction. The CMR protocol and standardized postprocessing have been published in detail previously. 17, 19 In brief, cine sequences were applied for the determination of LV function and volumes, T2-weighted imaging for measurement of the area at risk, and late enhancement imaging for assessment of infarct size and microvascular obstruction. Myocardial edema was defined as a mean signal intensity >2 SDs of remote myocardium in T2-weighted images. CMR images were analyzed by a blinded CMR core laboratory (University of Leipzig -Heart Center, Leipzig, Germany). Reproducibility, interobserver as well as intraobserver variability of the CMR core laboratory were reported previously. 22 Area at risk, infarct size, and microvascular obstruction are expressed as the percentage of LV volume (% LV). 23, 24 Myocardial salvage was quantified as the difference between the volume of increased T2 signal (area at risk) and the volume of late enhancement (infarct size). Myocardial salvage index was calculated as myocardial salvage divided by area at risk multiplied by 100. 25 In a subgroup of patients (n=662), we further determined left atrial (LA) ejection fraction as described previously. 26 Briefly, minimum and maximum LA volumes were defined as smallest and largest LA volume determined during the cardiac circle, respectively. LA volumes were delineated both in long-axis 2 chamber and 4 chamber view and final calculation of LA volumes was based on biplane measures.
Statistical Analysis
Continuous variables are presented as mean±SD or median with interquartile range (IQR) according to their distribution. Categorical variables are shown as frequencies with corresponding percentages. Differences between groups were tested by means of the t test and the Wilcoxon-Mann-Whitney U test. Proportions were compared by χ 2 -test and Fisher exact test as appropriate. We further built a multiple logistic regression model to identify predictors of MACE. To find relevant variables, we applied the least absolute shrinkage and selection operator procedure starting with all variables from Table 1 . 27 We standardized continuous variables and replaced some missing values by multiple imputation as 2 preliminary steps. 28 The least absolute shrinkage and selection operator procedure finds a preoptimal model without using P values. Variables with risk near 1 were omitted to get sparse models. These final models (logistic procedure with method enter) yielded the risk estimates inclusive 95% confidence intervals (CI). To ensure statistical robustness of the multiple regression model, we included the thrombolysis in myocardial infarction-risk score instead of the individual risk variables (age, diabetes mellitus, hypertension, heart rate, Killip class, weight, infarct location, and time to treatment) to reduce the number of parameters with respect to our sample size and total number of adverse events. In addition, net reclassification improvement and integrated discrimination improvement of the final multivariable regression model with and without AF was calculated. All tests were 2-tailed and the significance level is 0.05. The multiple imputation, least absolute shrinkage and selection operator procedures, and net reclassification 
Results
AF and Patient Characteristics
Information on heart rhythm was available in 786 (98.9%) patients ( Figure 1 ). The overall presence of AF was 6.1% (n=48). Table 1 shows the baseline characteristics of the overall cohort and according to the presence or absence of AF. Patients with AF were significantly older, more frequently females, had a worse cardiovascular risk profile except for smoking, had on average a lower blood pressure and a higher heart rate. Baseline procedural characteristics of the overall cohort and according to the presence or absence of AF are summarized in Table 2 . Median thrombolysis in myocardial infarction-risk score was significantly higher in patients with AF.
AF and CMR Findings
CMR scans were performed 3 (IQR, 2-4) days after STEMI in both groups (estimated median difference 0 days (95% CI, 0-1 days). Table 3 shows the CMR characteristics of all patients and their relation with AF. CMR infarct characteristic variables did not differ significantly between groups. Median LV ejection fraction was significantly lower in patients with AF compared with patients without AF 
Discussion
This multicenter study evaluated the impact of AF during hospitalization on CMR markers of myocardial and microvascular injury in patients with STEMI treated by PPCI. The key findings can be summarized as follows (1) age, comorbidities, and cardiac dysfunction assessed by CMR were associated with the presence of AF; (2) however, patients with AF had a similar amount of salvaged myocardium, infarct size, and microvascular injury when compared with patients without AF. (3) AF was associated with 12 months adverse outcomes, even after adjusting for clinical risk factors and CMR prognosis markers. Consequently, our results underscore the strong prognostic relevance of AF in the setting of contemporary revascularized STEMI, which is however not attributed to differences in PPCI efficacy (myocardial salvage), infarct size, or microvascular injury as determined by CMR imaging.
Incidence and Determinants of AF in STEMI
AF is frequently detected in patients treated with PPCI for STEMI, with a prevalence ranging between 5% to 20%. 1 We observed AF in 6% of patients, highlighting how commonly this scenario still occurs in contemporary practice. Compared with patients with sinus rhythm, those with AF were older and more likely to have other comorbidities. 5 Previous data suggested that increases in atrial pressure leading to AF might Myocardial damage determined by CMR was also suggested as a major determinant of LA volume, function as well as remodeling after STEMI, 29, 30 which are known risk factors for AF. Our data confirm a potential contribution of hemodynamic alterations including pump failure because cardiac dysfunction at CMR was associated with the presence of AF. Until now, however, no study has addressed the potential impact of AF on infarct severity, directly visualized by comprehensive CMR imaging in STEMI. Our study fills this knowledge gap in the literature by demonstrating that AF is not associated with differences in reperfusion success (myocardial salvage), infarct size, or microvascular injury. Therefore, other factors than infarct severity should move into focus of future research in this high-risk subgroup of patients with STEMI.
Prognostic Significance of AF in STEMI
In our analysis, AF during hospitalization for the index event was independently associated with an increased risk of the composite cardiovascular outcome at 12 months as well as the individual outcomes; all-cause mortality and new congestive heart failure. The relationship between AF and clinical outcomes has been analyzed previously. 5, 6 Batra et al 5 evaluated 155.071 hospital survivors of myocardial infarction between 2000 and 2009 in Swedish registries. As shown in this analysis, all types of AF in the setting of STEMI (new-onset AF with sinus rhythm at discharge, new-onset AF with AF at discharge, paroxysmal AF, and chronic AF) were associated with worse clinical prognosis with no major differences between AF subtypes. 5 Consequently and in line with our findings, the sole presence of AF before or after reperfusion (irrespective of AF subtype) should be recognized as critical clinical condition with negative impact on patient's outcome. AF should therefore be taken into account for the individual patient's risk stratification. Multiple risk scores, including the thrombolysis in myocardial infarction-risk score, the Primary Angioplasty in Myocardial Infarction risk score, or the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications risk score, have been developed to stratify patients with STEMI according to their risk of mortality and morbidity. [31] [32] [33] However, AF is not represented in these scores to date. Our results underline that studies considering AF in these risk scores are warranted to further improve their prognostic value, especially because the prevalence of AF is increasing, reflecting the increasing number of older patients and the pervasiveness of comorbidities. 34 In general, our and previous results of the correlation of AF with adverse prognosis might reflect that AF is a marker for worse clinical condition and structural heart disease. However, the exact mechanisms for the heightened risk of future cardiovascular events after STEMI are not fully understood. First, it has been shown that AF can facilitate the development of lifethreatening ventricular arrhythmias because of an enhanced electric instability of the myocardium. 35 This might at least partially explain the increased risk of MACE in STEMI patients with AF. Second, LA function and remodeling, which reflects a parallel ventricular-atrial remodeling is associated with an unfavorable prognosis after STEMI. 26, 29, 30 An increased heart rate in patients with AF results in an impaired oxygen supply to oxygen demand ratio aggravating these remodeling processes. 8, 36 In this study, patients with AF had a significantly worse LA function compared with patients without AF. As such, LA dysfunction in survivors of STEMI with AF might also contribute to the worse outcome. Third, antithrombotic treatment regimens of patients with AF and STEMI undergoing PPCI are complex and associated with an increased bleeding risk. 37 Fourth, AF and heart failure share pathophysiological mechanisms that contribute to the initiation and maintenance of the other. 38 Therefore, AF-induced heart failure is likely to contribute to the worse outcome of these patients. The mechanisms behind heart failure caused by AF have been studied in several studies. 38 AF may precipitate or exacerbate LV systolic dysfunction, 10 which is one of the most powerful markers indicating poor outcome after STEMI. 20 However, the mild difference in LV ejection fraction between patients with or without AF in our study unlikely explains the adverse outcome of patients with AF. AF is associated with tachycardia and shortening of diastolic filling time with irregular ventricular activation that impairs diastolic function and might therefore promote heart failure in STEMI patients with AF. Finally, there is inconsistent evidence for a potential pathophysiological link between AF and more severe myocardial damage with worse outcome as consequence. 12, 14 Our multicenter study is the first investigation demonstrating no difference in reperfusion success or irreversible myocardial injury between patients with or without AF, indicating that the amount of myocardial damage is not the mechanism by which AF has an adverse impact on patient's outcome. However, in accordance with previous data, we found a significant association between AF and worse LV and LA systolic function at CMR. To what extent AF is a cause or a consequence of myocardial dysfunction needs further investigation, but it is very likely that the development of either condition has a relevant detrimental impact on the other.
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Study Limitations
Several limitations of this study should be considered. The relative small sample size of our study is an important limitation and hence confirmation of our findings in larger studies is necessary. Information on heart rhythm during CMR acquisition is not available for the current study. We can therefore not exclude that AF during cine CMR acquisition might have influenced image quality and therefore measurement of LA and LV function. Because of ECG recording at 3 time points, some patients with AF might have been undetected and therefore misclassified into the sinus rhythm group. Also, we could not distinguish between preexisting and new-onset AF and thus further studies assessing potential differences in infarct characteristics in these 2 scenarios would be interesting. On the other hand, our data underscore that the simple information on the presence of AF during hospitalization for STEMI has strong prognostic implications in initial STEMI survivors. Various biomarkers, especially NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and high-sensitivity cardiac troponin provide valuable prognostic information in patients with AF. 39, 40 Indeed, recent risk stratification schemes including biomarkers (eg, ABC-stroke score) have shown very promising results for risk prediction. 39, 41 In our study, we found no difference in maximum creatine kinase between patients with or without AF; however, information on NT-proBNP and high-sensitivity cardiac troponin was not available precluding further insights into this interesting area of research. The impact and clinical significance of elevated NTproBNP and high-sensitivity cardiac troponin in STEMI patients with AF needs to be addressed in future studies.
LA strain analysis by CMR, which correlates with the degree of fibrofatty replacement at histological analysis and might reveal myocardial alterations of the LA even when conventional cine analysis is normal, 40, [42] [43] [44] was not available for the current analysis. Further studies evaluating the association between LA strain, LA ejection fraction, and AF in patients with STEMI are warranted. Finally, our data have no direct impact on the management of STEMI patients with AF. Further clinical studies are needed to explore potential clinical implications of these findings.
Conclusions
This study underlines the relevance of AF as an independent risk factor for future cardiovascular events in the setting of contemporary PPCI for STEMI. However, this heightened risk is not explained by differences in PPCI efficacy (myocardial salvage) or more pronounced myocardial damage as visualized by comprehensive CMR imaging. The results of our study should be taken into consideration when evaluating optimized treatment strategies for these high-risk patients with STEMI and concomitant AF.
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